WHO Sounds Warning Over Acute Lack of Obesity Jabs

Under a tenth of patients that would benefit from GLP-1 drugs including Wegovy can access them, states the World Health Organization as it issues its initial advice on the therapies.

Considering more than one billion people worldwide now obese, it is calling for more widespread and fairer access to GLP-1 medication.

Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.

"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are major obstacles to broad access to the jabs that can help people shift substantial weight, explains the agency.

Weight-Loss Drug Supply Crisis

Even under the current best projected scenario, the production of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.

The advice calls on nations and manufacturers to increase access, by measures such as voluntary licensing.

The intellectual property rights on the active ingredient – the main component of a leading brand – is set to lapse in multiple countries in 2026.

How Obesity Jabs Operate

GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and increase satiety so people consume fewer calories.

Individuals usually see weight reduction within a few weeks of commencing the regular doses.

Research suggests people may see weight return a year later of discontinuing the drug, as their typical food cravings come back.

To be carrying excess weight elevates your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.

Excess weight impacts individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.